M2 Presswire - Gilead Names John W. Madigan to Board and Merck Announces US Label Change for SINGULAIR(R).
M2 PRESSWIRE-14 December 2005-US Financial Network: Gilead Names John W. Madigan to Board and Merck Announces US Label Change for SINGULAIR(R)(C)1994-2005 M2 COMMUNICATIONS LTD RDATE:14122005 City of Industry, CA - Biotechnology industry news provided by Financial News USA (OTC: FNWU) Biopharmaceutical Company Gilead Sciences Inc.
Related Results
Popular prescription drugs
Gilead Names John W. Madigan to Board and Merck Announces US Label Change for…
Positive new data for Merck & Co’s Singulair.
For allergic rhinitis, two drugs found equivalent.(Pulmonary Medicine)(Drug o…
Drug patent expiration list. (Rx/Generic Drugs).(Brief Article)
(Nasdaq:GILD) said Tuesday it named John W. Madigan to its board, bringing the number of directors to 10. Madigan, 68, is the retired chairman and chief executive of Chicago newspaper publisher Tribune Co., the company said. He was also an investment …
Read the rest of this article with a Free Trial at HighBeam Research.
